Login to Your Account

Sanofi Takes Options on Oxford Biomedica's Gene Therapies

By Nuala Moran
Staff Writer

Thursday, July 5, 2012

LONDON – Oxford Biomedica plc said that Sanofi SA is taking up its options on two gene therapy products for treating retinal disease, triggering a $3 million milestone and providing the impetus for a placing and open offer to raise up to £16 million (US$25 million).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription